Buprenorphine oral lyophilisate (Espranor®) in the substitution treatment of opioid dependence: a profile of its use Katherine A. Lyseng-Williamson Adis Drug Q&A 08 May 2017 Pages: 241 - 248
Chlormethine 160 mcg/g gel in mycosis fungoides-type cutaneous T-cell lymphoma: a profile of its use in the EU Lesley J. Scott Adis Drug Q&A 06 May 2017 Pages: 249 - 253
Vorapaxar in the long-term secondary prevention of atherothrombotic events: a profile of its use in the USA Kate McKeageKatherine A. Lyseng-WilliamsonJames E. Frampton Adis Drug Q&A 06 May 2017 Pages: 254 - 259
Extrafine beclometasone dipropionate/formoterol fumarate metered-dose and dry-powder inhalers in asthma and chronic obstructive pulmonary disease: a profile of their use Sohita Dhillon Adis Drug Q&A 31 March 2017 Pages: 260 - 271
Individualize treatment for vernal keratoconjunctivitis based on clinical features and personal preferences Adis Medical Writers Disease Management 25 April 2017 Pages: 272 - 276
Medications that affect CNS neurotransmitter levels may induce tactile hallucinations Adis Medical Writers Drug Reactions and Interactions 22 March 2017 Pages: 279 - 282
Characteristics and quality of adverse drug reaction reporting: a comparison of pharmacists with other healthcare providers at a multi-specialty hospital in Qatar Noor AlsalimyDana ElkhalifaAhmed Awaisu Short Communication 28 April 2017 Pages: 283 - 289
A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus Shery JacobAnroop B. Nair Review Article 27 April 2017 Pages: 290 - 301
Erratum to: Cystadrops® (cysteamine hydrochloride 0.55% viscous eye-drops solution) in treating corneal cystine crystal deposits in patients with cystinosis: a profile of its use Katherine A. Lyseng-Williamson Erratum 20 April 2017 Pages: 302 - 302
